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In the clinical management of heart failure, two truths have
become evident: Excess is harmful; and patience is a virtue.
The first truth relates to the stimulation of the sympathetic and
renin–angiotensin systems in response to the acute hemody-
namic derangements of heart failure. These systems promote
sodium and water retention, vasoconstriction and contractility
in an effort to enhance cardiac performance through physio-
logic mechanisms (1). However, continued neurohormonal
activation elicits harmful pathophysiologic consequences, such
as attenuation of cardiopulmonary baroreflex inhibition, down-
regulation of beta1-adrenoreceptor density, uncoupling of
beta-adrenoreceptors from the G-protein–adenylcyclase com-
plex, myocyte loss, systemic vasoconstriction and, ultimately,
ventricular remodeling and increased wall stress (1–3). Thus,
neurohormonal activation leads to the inevitable progression
of heart failure after resolution of the initial cardiopathic
insult—the so-called neurohormonal hypothesis (1). Presum-
ing this hypothesis to be valid, treatments that promote the
physiologic aberrations of neurohormonal activation should
produce hemodynamic benefits in the short term but acceler-
ate heart failure progression in the long term. Such is the case
with the prolonged use of nonglycoside inotropic agents such
as the phosphodiesterase inhibitors (4–7). Alternatively, dis-
ruption of neurohormonal activation should slow heart failure
progression, as is the case with the angiotensin-converting
enzyme (ACE) inhibitors (8–10).
The second truth (a Stoic principle) relates to the actual
application of medications for heart failure. Some drugs, such
as ACE inhibitors, should not be immediately applied at full
doses in patients with symptomatic heart failure because these
drugs may not be tolerated. Hypotension often limits the initial
dosing of ACE inhibitors. As a result, ACE inhibitors should
be started at lower doses and gradually titrated upward. A
successful titration of ACE inhibitors to therapeutic doses
results in a delay in heart failure progression and improved
survival. Patience proves prudent. Similar principles apply to
beta-adrenergic blocking agents. Impaired inotropy and in-
creased systemic vascular resistance result in exacerbations of
heart failure when beta-adrenergic blockers are administered
over too short a period or at too high a dose in patients with
chronic heart failure (2,11). Doses must be started low and
patiently increased to overcome short-term intolerance. Even
so, in patients with mild to moderate symptomatic heart
failure, the initial titration of beta-adrenergic blockers will fail
in 4% to 8% (12–17). For those patients who tolerate beta-
adrenergic blockers, delayed heart failure progression, im-
proved cardiac performance and improved survival have been
demonstrated in several studies (12–16).
The use of beta-adrenergic blockers in patients with New
York Heart Association functional class IV or refractory heart
failure has not been adequately studied. Clinical experience
tells us that a substantially greater proportion of patients will
be intolerant of beta-adrenergic blockers (10,11,18). Because
ACE inhibitors are beneficial in patients in functional class IV
(8), one would also expect beta-adrenergic blockers to be of
benefit if only they could be successfully applied. In such
patients, the initial administration of beta-adrenergic blockers
may be difficult, but quiet determination will most likely prove
fruitful in the long run. In an unassuming and nondramatic
manner, beta-adrenergic blockers will dampen the sympathetic
nervous system, slow the heart rate and improve left ventric-
ular ejection fraction and may prolong survival. In this manner,
the principles of stoicism (patience and endurance) may be the
key to success of beta-adrenergic blocker therapy in severe
heart failure.
However, there will still be a certain fraction of patients
with severe or refractory heart failure unable to tolerate
beta-adrenergic blockers at any doses or over any titration
period, regardless of their or their physician’s determination.
How, then, to overcome short-term intolerance? Why not
change philosophies and take an Epicurean approach? Phos-
phodiesterase inhibitors (the inodilators) provide rapid and
dramatic improvements in cardiac performance, even in pa-
tients with severe heart failure, producing rapid relief of heart
failure symptoms. But, in true Epicurean fashion, prolonged
use of inotropic agents shortens survival, at least in part by
promoting myocyte loss as well as arrhythmogenesis and
sudden death (4–7,19,20). In contrast, beta-adrenergic block-
ers protect against myocyte loss, are antiarrhythmogenic and
may potentially prevent sudden death (2,21). When used
together, phosphodiesterase inhibitors may conceivably over-
come the initial hemodynamic intolerance of beta-adrenergic
blockers in patients with severe heart failure. Beta-adrenergic
blockers will quiet the sympathetic nervous system, and the
culmination of this combination would be the expression of the
advantages of both and the cancellation of their negative
qualities. The conjoining of Stoic and Epicurean philosophies
may prove symbiotic in the management of refractory heart
failure.
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So now we are faced with two common and practical issues:
how to wean the patient with refractory heart failure from
intravenous inotropic agents and then how to apply beta-
adrenergic blockers to reduce future episodes of cardiac
decompensation? Shakar et al. (22), in this issue of the
Journal, chose to use the oral phosphodiesterase inhibitor
enoximone to tackle both problems simultaneously. They
intended to wean patients from intravenous inotropic agents by
using oral enoximone (23), continue the enoximone for a
period of time to attain hemodynamic stabilization, initiate and
titrate metoprolol (a beta1-selective adrenoceptor blocker) and
then wean the patients from enoximone while continuing
metoprolol. Enoximone was an obvious choice for this task
because it was available in oral formulation. This drug and
drugs of its class promote contractility by preventing the
intracellular degradation of cyclic adenosine monophosphate,
a mechanism independent of beta-adrenergic receptor signal-
ing (2,6,24). Thus, metoprolol would not prevent the desired
inotropic effects of enoximone. Preliminary data have sug-
gested that the combination of phosphodiesterase inhibitors
and beta-adrenergic receptor blockers in heart failure is toler-
ated and that hemodynamic changes are beneficial (25,26).
Although the main presumption is that the enhanced contrac-
tility imparted by phosphodiesterase inhibitors is the mecha-
nism that supports the initiation of beta-adrenergic blockade,
patients with refractory heart failure taking intravenous adren-
ergic agonists, when stabilized, also seem to tolerate beta-
blocker initiation (27). Because beta-adrenergic blockers at-
tenuate the inotropic effects of beta-adrenergic agonists,
peripheral effects of inotropic/inodilator agents may be impor-
tant in allowing the administration of beta-adrenergic blockers.
Shakar et al. (22) specifically targeted patients with func-
tional class IV heart failure. Thirty patients were studied, 18 of
whom met the definition of refractory heart failure (28) and
were receiving intravenous inotropic agents, 9 of whom had
symptoms too unstable to attempt beta-adrenergic blockade,
and 3 of whom were known to be previously intolerant of
beta-adrenergic blockers. It is doubtful any of these patients
could tolerate beta-adrenergic blockade. Symptoms were suc-
cessfully stabilized with enoximone in all patients (although
enoximone was discontinued in one patient 5 months later
because of syncope), and all 18 patients receiving intravenous
inotropic agents were successfully weaned from their drugs
with oral enoximone. Twenty-eight of 30 patients were ulti-
mately challenged with metoprolol, and 23 (82%) tolerated the
drug. These patients continued metoprolol therapy until death
or heart transplantation, a mean of 21 months (lead follow-up,
nearly 7 years). Only one-half of patients could be weaned
from enoximone while continuing metoprolol, lending cre-
dence to the hemodynamic supportive role that enoximone was
providing. Metoprolol (with or without enoximone) produced
a sustained improvement in left ventricular ejection fraction, in
functional class and in the reduction of the number of hospital
admissions over the course of metoprolol administration,
suggesting a real impact on the progression of heart failure in
these severely ill patients. One of the major observations of this
study was that survival appeared to be improved in patients in
functional class IV by the addition of metoprolol to triple
therapy. Only 5 patients (17%) died of cardiac causes, and
one-half never required heart transplantation (22). The 1-year
survival rate (censored at the time of heart transplantation) for
patients taking metoprolol was 81% (95% confidence interval
64% to 98%), substantially better than the 1-year survival of
patients in functional class IV in the experimental arm of the
CONSENSUS I trial (54%) or the control arm of the PROM-
ISE trial (61%) (5,8). This comparatively better survival with
metoprolol is presumptive evidence that beta-adrenergic
blockade is beneficial to patients with functional class IV heart
failure receiving triple therapy and that enoximone makes this
a tolerated treatment approach. In other words, enoximone
served as a bridge to beta-blocker therapy.
Surprisingly, because one-half of patients could not be
weaned from enoximone, Shakar et al. (22) have unwittingly
broached the subject of combining Epicurean and Stoic prin-
ciples over the long term. The apparent improved survival in
the study suggests, as hypothesized, that the combination of
phosphodiesterase inhibitors with beta-adrenergic blockers
may produce all the benefits of both without the liabilities of
either. “Quintuple therapy” may therefore be a legitimate
consideration in patients with severe heart failure.
But let us not get ahead of ourselves. This optimism evolves
from a study with several problems: 1) The study involved only
30 patients compared with 253 patients in functional class IV in
the CONSENSUS I trial and 457 such patients in the PROM-
ISE trial (5,8). Despite this huge difference in subject numbers,
a p value of 0.01 was calculated comparing the 1-year survival
rate of metoprolol-treated patients with that of patients in the
CONSENSUS I and PROMISE trials who received triple
therapy only (22). Still, we must keep in mind that only several
more deaths in the study might have raised considerable doubt
as to whether metoprolol confers a survival advantage in these
patients. 2) The study was retrospective and as such the
influence of hidden biases cannot be excluded. For instance, 30
patients were studied, but they are not described as “consec-
utive,” which implies that some discrimination was utilized in
their inclusion that could influence the tolerability and out-
come of beta-adrenergic blocker therapy in either a favorable
or negative direction. More problematic, was enoximone un-
successful in weaning some patients from intravenous inotrop-
ic therapy, so that they never underwent metoprolol challenge
and were thus not included in this study? Could some of these
patients have somehow tolerated metoprolol and have accrued
long-term benefit? This scenario is not likely, but their “inten-
tion to treat” inclusion could have provided a more meaningful
perspective of the proposed enoximone/metoprolol treatment
approach to refractory heart failure. 3) We do not actually
have a historical denominator that delineates the proportion of
patients in functional class IV intolerant of metoprolol. We can
therefore only infer that the use of enoximone represents an
advance. 4) A true control group was obviously lacking in this
study. 5) The findings of this study using metoprolol may not
be generalizable to the third-generation beta-adrenergic block-
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ers, such as carvedilol or bucindolol. 6) No prospective neuro-
hormonal data were generated to demonstrate the proposed
dampening of the sympathetic nervous system in these pa-
tients, one-half of whom continued receiving enoximone. The
demonstration of sustained, diminished neurohormonal levels
in those patients receiving metoprolol (6enoximone) would
have been compelling supportive evidence of the favorable
effects of beta-adrenergic blockade on the natural history of
severe heart failure, albeit that a demonstration of attenuated
neurohormonal status has not been uniformly shown in beta-
blocker trials (29–31).
Where does the information from this small pilot study lead
us? We need to determine with certainty whether beta-
adrenergic blockade produces a survival advantage in patients
with severe or refractory heart failure over triple-therapy
alone. This determination will require prospective, random-
ized trials. The study by Shakar et al. (22) provides us with a
means to eliminate the problem of beta-adrenergic blocker
intolerance, which would confound such prospective, random-
ized trials. The use of up-front enoximone would avoid the bias
introduced by drug intolerability during run-in test periods that
determine a subject’s eligibility for randomization and have
plagued previous beta-adrenergic blocker trials (12–18). The
study also hints at a solution to the problem facing many
outpatients with end-stage heart failure who are receiving
intravenous inodilator therapy: the Epicurean trade-off of
improved heart failure symptoms in the short run but short-
ened survival in the long run. The study by Shakar et al. (22)
suggests that a sizable fraction of these outpatients should
tolerate the initiation and titration of beta-adrenergic blockers.
Many of these patients will be weanable from the intravenous
inodilators—hopefully, to enjoy the potential benefits of heart
failure symptom palliation without the expectation of short-
ened survival.
We thank Ronald Sutherland for expert preparation of the manuscript.
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